Horizon Therapeutics Ltd
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
118 / 1361
Position in country
56 / 187
Return on Assets, %
4.8
-40.3
Net income margin, %
13.4
-180
EBITDA margin, %
25
-168.2
Debt to Equity, %
48.1
3.2
Intangible assets and goodwill, %
46.3
0.2
Revenue CAGR 3Y, %
40.8
12.5
Total Equity change 1Y, %
4.7
-9
Revenue Y, % chg
0.4
0
P/BV
45
1.8
EV/EBITDA
23.2
-1.6
Payout Ratio, %
0
0
Competitors
Ranks
-
Alkermes Plc
00%
-
Horizon Therapeutics Ltd
00%
-
Vertex Pharmaceuticals Inc
00%
-
CSL Ltd
00%
-
Regeneron Pharmaceuticals Inc
00%
-
Gilead Sciences Inc
00%
-
Seagen Inc
00%
-
Amgen Inc
00%
-
Prothena Corporation PLC
00%
-
AbbVie Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
Ireland; Republic of
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
26632
Ticker
HZNP.O
ISIN
IE00BQPVQZ61
IPO date
Availability on Russian exchanges
No
Reporting for
2023-08-08
Date fact. publication of reports
2023-06-30
Company Description
Horizon Therapeutics plc is a biotechnology company that is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and serious inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The Company has two reportable segments: the orphan and the inflammation segment. The orphan segment includes the medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA and also the Company’s research and development (R&D) programs. TEPEZZA is a monoclonal antibody and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). KRYSTEXXA is an infused medicine for uncontrolled gout. The Company's other orphan segment medicines, RAVICTI, PROCYSBI and ACTIMMUNE, treats serious chronic diseases. The inflammation segment includes PENNSAID 2%, DUEXIS, RAYOS and VIMOVO medicines.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: